Prot #CLGX818AUS03: Modular Phase II Study to Link Targeted Therapy to Patients with Pathway Activated Tumors: Module 4 - LGX818 for Patients with BRAFV600 Mutated Tumors

Project: Research project

Project Details

StatusFinished
Effective start/end date2/13/14 → 12/31/17

Funding

  • United BioSource LLC (Prot #CLGX818AUS03 // Prot #CLGX818AUS03)
  • Novartis Pharmaceuticals Corporation (Prot #CLGX818AUS03 // Prot #CLGX818AUS03)